DK1191926T3 - Ny omeprazol- og (S)-omeprazolformulering - Google Patents

Ny omeprazol- og (S)-omeprazolformulering

Info

Publication number
DK1191926T3
DK1191926T3 DK00946614T DK00946614T DK1191926T3 DK 1191926 T3 DK1191926 T3 DK 1191926T3 DK 00946614 T DK00946614 T DK 00946614T DK 00946614 T DK00946614 T DK 00946614T DK 1191926 T3 DK1191926 T3 DK 1191926T3
Authority
DK
Denmark
Prior art keywords
omeprazole
new
formulation
dosage form
core material
Prior art date
Application number
DK00946614T
Other languages
Danish (da)
English (en)
Inventor
Per Johan Lundberg
Brita Sjoeblom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1191926T3 publication Critical patent/DK1191926T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00946614T 1999-06-22 2000-06-20 Ny omeprazol- og (S)-omeprazolformulering DK1191926T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902386A SE9902386D0 (sv) 1999-06-22 1999-06-22 New formulation
PCT/SE2000/001310 WO2000078293A1 (en) 1999-06-22 2000-06-20 New formulation

Publications (1)

Publication Number Publication Date
DK1191926T3 true DK1191926T3 (da) 2005-06-13

Family

ID=20416209

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00946614T DK1191926T3 (da) 1999-06-22 2000-06-20 Ny omeprazol- og (S)-omeprazolformulering

Country Status (29)

Country Link
EP (1) EP1191926B1 (pt)
JP (1) JP2003502359A (pt)
KR (1) KR100717661B1 (pt)
CN (1) CN1243547C (pt)
AT (1) ATE291901T1 (pt)
AU (1) AU778158B2 (pt)
BR (1) BR0011894A (pt)
CA (1) CA2376226C (pt)
CZ (1) CZ20014579A3 (pt)
DE (1) DE60019116T2 (pt)
DK (1) DK1191926T3 (pt)
EE (1) EE200100693A (pt)
ES (1) ES2235912T3 (pt)
HK (1) HK1044480B (pt)
HU (1) HUP0201489A3 (pt)
IL (2) IL146818A0 (pt)
IS (1) IS6209A (pt)
MX (1) MXPA01012636A (pt)
NO (1) NO20016346L (pt)
NZ (1) NZ516186A (pt)
PL (1) PL352873A1 (pt)
PT (1) PT1191926E (pt)
RU (1) RU2240110C2 (pt)
SE (1) SE9902386D0 (pt)
SK (1) SK285326B6 (pt)
TR (1) TR200103693T2 (pt)
UA (1) UA73302C2 (pt)
WO (1) WO2000078293A1 (pt)
ZA (1) ZA200109803B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
SI21402A (sl) 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
AU2004216405A1 (en) * 2003-02-28 2004-09-10 Ranbaxy Laboratories Limited Stable pharmaceutical composition of rabeprazole and processes for their preparation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
EP1696889A1 (en) * 2003-08-28 2006-09-06 Ranbaxy Laboratories, Ltd. Pharmaceutical compositions of benzimidazole and processes for their preparation
CA2536902A1 (en) * 2003-09-03 2005-03-10 Agi Therapeutics Limited Proton pump inhibitor formulations, and methods of preparing and using such formulations
US7699964B2 (en) 2004-02-09 2010-04-20 Abbott Diabetes Care Inc. Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8165651B2 (en) 2004-02-09 2012-04-24 Abbott Diabetes Care Inc. Analyte sensor, and associated system and method employing a catalytic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
JP2008510804A (ja) * 2004-08-23 2008-04-10 オークランド ユニサービシズ リミテッド 胃の治療法およびそのための組成物
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
FR2885526B1 (fr) * 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
KR20080081071A (ko) * 2005-12-28 2008-09-05 다케다 야쿠힌 고교 가부시키가이샤 방출 제어 고형 제제
US7885698B2 (en) 2006-02-28 2011-02-08 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
RU2467747C2 (ru) 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
MX2011002515A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita.
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
BR112013029199B1 (pt) * 2011-05-13 2022-02-08 Eb Ip Hybritabs B.V. Dispositivo de distribuição de dois fármacos
EP2586429A1 (en) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Multi-unit drug delivery device for pulsatile or sustained release
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
WO2013122554A1 (en) 2012-02-14 2013-08-22 Mahmut Bilgic Pellet formulations comprising esomeprazole
CN103127026B (zh) * 2013-02-05 2017-02-15 悦康药业集团有限公司 一种奥美拉唑肠溶胶囊及其制备方法
AU2014374361B9 (en) 2013-12-31 2019-07-04 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
RU2614730C1 (ru) * 2016-02-05 2017-03-28 Игорь Юрьевич Чичерин Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
US10736855B2 (en) * 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
JP6462625B2 (ja) * 2016-04-06 2019-01-30 ニプロ株式会社 カルシウムブロッカーを含有する錠剤
JP6426115B2 (ja) * 2016-04-06 2018-11-21 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ZA979937B (en) * 1996-11-06 1999-05-18 Sharmatek Inc Delayed delivery system for acid-sensitive drugs
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
ATE303809T1 (de) * 1997-12-08 2005-09-15 Altana Pharma Ag Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
AU772726B2 (en) * 1998-08-12 2004-05-06 Takeda Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles

Also Published As

Publication number Publication date
HK1044480A1 (en) 2002-10-25
CN1243547C (zh) 2006-03-01
KR20020012002A (ko) 2002-02-09
PT1191926E (pt) 2005-07-29
EE200100693A (et) 2003-02-17
CZ20014579A3 (cs) 2002-05-15
NO20016346L (no) 2002-02-18
IL146818A0 (en) 2002-07-25
HK1044480B (zh) 2005-08-26
IS6209A (is) 2001-12-21
AU778158B2 (en) 2004-11-18
EP1191926A1 (en) 2002-04-03
AU6034400A (en) 2001-01-09
CN1356893A (zh) 2002-07-03
PL352873A1 (en) 2003-09-08
UA73302C2 (en) 2005-07-15
RU2240110C2 (ru) 2004-11-20
MXPA01012636A (es) 2002-06-21
HUP0201489A3 (en) 2004-05-28
EP1191926B1 (en) 2005-03-30
HUP0201489A2 (hu) 2002-11-28
JP2003502359A (ja) 2003-01-21
BR0011894A (pt) 2002-04-02
KR100717661B1 (ko) 2007-05-14
SK285326B6 (sk) 2006-11-03
CA2376226A1 (en) 2000-12-28
ZA200109803B (en) 2003-02-28
SE9902386D0 (sv) 1999-06-22
DE60019116D1 (de) 2005-05-04
IL146818A (en) 2007-10-31
NO20016346D0 (no) 2001-12-21
SK18252001A3 (sk) 2002-09-10
TR200103693T2 (tr) 2002-05-21
NZ516186A (en) 2003-11-28
ATE291901T1 (de) 2005-04-15
CA2376226C (en) 2009-10-20
WO2000078293A1 (en) 2000-12-28
ES2235912T3 (es) 2005-07-16
DE60019116T2 (de) 2006-02-09

Similar Documents

Publication Publication Date Title
DK1191926T3 (da) Ny omeprazol- og (S)-omeprazolformulering
NO20012222D0 (no) Farmasöytisk formulering innbefattende omeprazol
IS2856B (is) Lyfjablanda úr ómeprasól
EE200000329A (et) Oraalne manustamisvorm happes ebapüsivate toimeainete tarbeks, selle valmistamismeetod ja happes ebapüsivat toimeainet sisaldava toimeaineühiku kasutamine
EE05383B1 (et) Polarlkarboksamiidhendid,ÁnendeÁvalmistamineÁjaÁkasutamineÁlipiiditasetÁalandavateÁtoimeainetenaÁningÁneidÁsisaldavÁfarmatseutilineÁkompositsioon
MY129356A (en) Electrospun pharmaceutical compositions
ATE431738T1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
EE200100505A (et) Modifitseeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis, hüdrofiilnekontrollitud vabanemisega preparaat, selle valmistamismeetod ja kasutamine ning ravimvorm
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
LV10268A (lv) Terapeitiski aktivs benzimidazols un ta iegusanas panemiens
ATE254851T1 (de) Iod-herstellungszusammensetzung
EP0291269A3 (en) Anti-tumour sulfonyl urea derivatives
SE9604752D0 (sv) Formulation and use
GB0006897D0 (en) Medicaments
MY127600A (en) Solid oral dosage forms of valsartan